Aug 09, 2017

Hope is on the way for one of the world’s most common sexual problems

Hope is on the way for one of the world’s most common sexual problems

Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age. 

Go to article (external link)